ArticleCancer research2010
In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.
Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Sex Steroid Hormone Regulation of T-Cell Function and Antitumor Immunity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- High Pretreatment DHEA Is Associated with Inferior Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer.Cancers · 2024Article
- Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas.Frontiers in immunology · 2022Article
- A marrow-minded look at immune checkpoint blockade resistance in metastatic castration resistant prostate cancer.Translational andrology and urology · 2021Article
- A QSP model of prostate cancer immunotherapy to identify effective combination therapies.Scientific reports · 2020Article
- Tuberous Sclerosis Complex as Disease Model for Investigating mTOR-Related Gliopathy During Epileptogenesis.Frontiers in neurology · 2020Review
- Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer.Frontiers in immunology · 2020Review
- Systematically understanding the immunity leading to CRPC progression.PLoS computational biology · 2019Article
- Androgen deprivation and immunotherapy for the treatment of prostate cancer.Endocrine-related cancer · 2017Review
- Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.Cancer immunology research · 2017Article
- DNA vaccines for prostate cancer.Pharmacology & therapeutics · 2017Review
- Immune mediators in the tumor microenvironment of prostate cancer.Chinese journal of cancer · 2017Review
- Preclinical and clinical development of DNA vaccines for prostate cancer.Urologic oncology · 2016Review
- Prediction of treatment efficacy for prostate cancer using a mathematical model.Scientific reports · 2016Article
- Exploiting synergy: immune-based combinations in the treatment of prostate cancer.Frontiers in oncology · 2014Review
- Opposing effects of androgen ablation on immune function in prostate cancer.Oncoimmunology · 2012Article
- T cells localized to the androgen-deprived prostate are TH1 and TH17 biased.The Prostate · 2012Article
- Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells.Cancer research · 2012Article
- The PCa Tumor Microenvironment.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2011Article
- Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activity.Cancer immunology, immunotherapy : CII · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
There is no effective treatment for prostate cancer arising after androgen ablation. Previous studies have analyzed the short-term effects of androgen ablation on the immune system and suggest an abatement of immune suppression by hormone removal. Because castration-resistant disease can arise years after treatment, it is crucial to determine the duration of immune potentiation by castration. Because immunotherapeutic efficacy is determined by the balance of immune cell subsets and their location within the tumor, we assessed the acute and chronic effect of androgen ablation on the localization of T-cell subsets within castration-resistant murine prostate cancer. We observed a transient increase in CD4+ and CD8+ T-cell numbers at the residual tumor after androgen ablation. More than 2 months later, regulatory T cells (Treg) were increasingly found within prostate epithelium, whereas CTLs, which were evenly distributed before androgen ablation, became sequestered within stroma. Anti-CD25 antibody administration along with castration enhanced CTL access to cancerous glands but did not increase effector function. Intraprostatic injection of LIGHT-expressing tumor cells increased the proportion of CD8+ T cells with functional capacity within the cancerous gland. In addition, Treg depletion within the tumor was enhanced. Together, these manipulations significantly reduced castration-resistant tumor burden. Thus, our results indicate that immune modulations, which prevent Treg accumulation and augment effector cell infiltration of prostatic epithelium, may be effective in reducing tumor burden or preventing tumor recurrence after androgen ablation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.